Kathryne Carr

Partner
Tall Oaks Capital Partners LLC

Kathryne Carr is a founding partner at Tall Oaks Capital Partners LLC, where her portfolio responsibilities include Aldagen, Biolex and MaxCyte. Prior to her association with Tall Oaks Capital, she co-founded Whetstone Partners LLC in 1996 to help fund and grow new businesses in the health care sector. Whetstone Partners’ clients included a number of seed and early-stage companies that originated in several academic research institutions. Whetstone also managed Platform Technology Holdings, an investor in several medical device companies, including SmartPill Diagnostics and Minrad International (AMEX: BUF).

Carr has held several executive and managerial positions, including vice president of operations for Insmed Pharmaceuticals; project manager for Innotage Management, an investment management firm for health care start-up companies; and director of investor and public relations for Genetic Systems Corporation before its acquisition by Bristol Myers. In addition, Carr was a technical staff member at MITRE Corporation and a market analyst for the Marketing Corporation of America.

Carr is a member of the executive committee and board of directors for SEBIO, the University of Virginia Patent Foundation and the U.Va.–Wallace H. Coulter Foundation Translational Research Partnership. Carr is a graduate of Allegheny College with B.A. in political science in addition to graduate studies in finance at American University.